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1. Introduction 
Objective: Neuronal and Mixed Neuronal-glial Tumors of the Central Nervous System are 
frequently encountered in the neurosurgical practice. Differentiation of neuronal tumors from the 
more common glial tumors is crucial because neuronal tumors have favorable clinical outcomes and are 
generally curable with total surgical resection alone, whereas gliomas typically require further chemo- 
radiotherapy depending on their histologic grade and have poor prognosis. At histopathologic analysis, 
neuronal tumors are usually classified as pure neuronal cell tumors (gangliocytoma, Lhermitte-Duclos 
disease (dysplastic cerebellar gangliocytoma], central neurocytoma) and mixed neuronal-glial tumors 
(ganglioglioma, desmoplastic infantile ganglioglioma, dysembryoplastic neuroepithelial tumor, 
ganglioneuroma) In this chapter, we review the WHO classification of each type of neuroepithelial cell 
tumours and the incidence and distribution. The clinical presentation and neuroimaging will also be 
briefed, then we describe the specific histopathologic characteristics, immunohistochemestry and 
genetic suscipitability of the various neuronal tumors of the central nervous system and finally 
demonstrate the outcome of these lesions. 
2. Contents  
2.1. Ganglioglioma and gangliocytoma 
Ganglioglioma and gangliocytoma are well-differentiated, slowly growing benign 
neuroepithelial tumors. with World Health Organization (WHO) grade I. higher grade is 
based on the degree of malignancy in the glial-cell component. They represent around 1% of 
all central nervous system (CNS) tumors, However it is frequently oencountered in children 
and young adults between age 8 and 25 years. Gangliogliomas contain mature neoplastic 
neuronal cells, neoplastic glial cells, astrocytic cells, and ganglion cells, and may display 
mitotic activity. These lesions are curable by total removal.  
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2.2. Central neurocytoma and extraventricular neurocytoma 
Central neurocytoma and extraventricular neurocytoma are WHO grade II tumors 
composed of regular rounded cells that have undergone neuronal differentiation. Central 
neurocytomas are typicaly located within the lateral ventricles just next to the foramen of 
Monro, whereas extraventricular neurocytomas are located within the brain parenchyma. 
Both characteristically occur in young adults. The outcome is favorable after complete 
resectioning.  
2.3. Dysembryoplastic neuroepithelial tumor 
Dysembryoplastic neuroepithelial tumor (DNT) is frequently a benign, supratentorial glial-
neuronal WHO grade I tumor. DNT occur mainly in children or young adults, who usually 
present with intractable partial complex seizure. Characterized by a predominantly cortical 
location, DNT histopathologically exhibits a complex columnar and multinodular 
architecture, and is often associated with cortical dysplasia.  
2.4. Desmoplastic infantile astrocytoma and desmoplastic infantile 
ganglioglioma  
Desmoplastic infantile astrocytomas (DIAs) and desmoplastic infantile gangliogliomas 
(DIGs) are almost WHO grade I tumors that are often cystic and commonly occur in infants. 
Composed of a prominent desmoplastic stroma with neuroepithelial components, mainly 
neoplastic astrocytes in DIAs or astrocytes together with variable neuronal components in 
DIGs, they involve the cerebral cortex and leptomeninges, and are often adherent to the 
dura. The natural course is benign. 
2.5. Rosette-forming glioneuronal tumor of the fourth ventricle 
Rosette-forming glioneuronal tumor of the fourth ventricle (RGNT) is a usually rare and 
slowly growing WHO grade I tumor. It is commonly affecting young adults, RGNT is 
composed of two distinct histological cells types; uniform neurocytes which form rosettes 
and/or perivascular pseudorosettes and astrocytic cells similar to pilocytic astrocytomas. 
The prognosis is good upon surgical removal.  
2.6. Cerebellar liponeurocytoma 
This rare type of cerebellar tumors is WHO grade II tumor that typically occurs in adults. It 
is Composed of neuronal, astrocytic, and some lipomatous cells, they tend to recur after 
initial treatment.  
2.7. Papillary glio-neuronal tumor 
Papillary glio-neuronal tumors is a well defined and benign with WHO grade I. the natural 
course is insidius. It is composed of flat to cuboidal, GFAP-positive astrocytes lining 
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hyalinized vascular pseudo-papillae and synaptophysin-positive interpapillary sheets of 
neuronal cells. Upon microscopy, it exhibits different sizes of large and intermediate neuron 
“ganglioid” cells.  
2.8. Spinal paraganglioma 
Spinal paraganglioma is encapsulated, benign, neuro-endocrine WHO grade I tumor. 
Arising from neural crest cells and composed of segmental or collateral autonomic ganglia 
(paraganglia), It is primarily involving the cauda equine and filum terminale region. The 
uniform main cells exhibit neuronal differentiation and forming compact nests (Zellballen) 
surrounded by cells and a delicate capillary network within the CNS. 
3. Gangliogliomas and gangliocytomas 
3.1. Definition  
Gangliogliomas and gangliocytomas are well-differentiated, slowly growing benign 
neuroepithelial neoplasms that consist of neoplastic, mature ganglion cells. Both 
gangliogliomas and gangliocytomas are a type of neuroepithelial tumor that is the most 
frequent pathology observed in patients with long-term epilepsy. A gangliocytoma in the 
absence of neoplastic glial-cell development and a ganglioglioma in the presence of 
neoplastic glial-cell development. (1) 
3.2. WHO grading 
Gangliocytomas and most gangliogliomas are categorized as WHO grade I tumors (1).  
Some gangliogliomas with anaplastic features of the glial component are categorized as 
WHO grade III tumors (anaplastic gangliogliomas). Criteria for grade II types has also been 
suggested (2, 3). 
3.3. Incidence and gender distribution  
These uncommon neoplastic lesions represent only 0.4% of all CNS tumors and 1.3% of all 
brain tumors (3,4). The age of patients is variable, ranging from 2 months to 70 years. Data 
from 5 large series of a total of 626 patients indicate an average age at diagnosis ranging 
from 8.5 to 25 years and a male: female ratio ranging from 1.1:1 to 1.9:1 (5,6,7,8). In one 
study, the mean age in children at diagnosis is 9.5 years, with a slight female prevalence 
(9). 
3.4. Localization 
The vast majority of gangliogliomas (>70%) occur in the temporal lobe. However, 
Gangliocytomas and most gangliogliomas may occur throughout the CNS, including in the 
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cerebrum, brain stem, cerebellum, spinal cord, optic nerves, and pituitary and pineal glands. 
(2, 6, 7, 8, 10).  
3.5. Clinical features 
Variable clinical symptoms of gangliocytomas and most gangliogliomas are encountered 
and related to tumor size and site. Seizure is usually the initial presenting symptoms. 
Gangliocytomas and gangliogliomas are the most common tumors associated with chronic 
and intractable temporal lobe epilepsy and observed in 15% to 25% of patients undergoing 
epilepsy surgery (11,12).duration of symptoms ranging from 1 month to 50 years before 
diagnosis, with a median interval of 6 to 25 years (6,7,8). Tumors affecting the brain stem or 
spinal cord frequently present with crossed paresis or long-tract lesion and sphincteric 
disorder of a mean duration of 1.25 and 1.4 years, respectively (6).  
3.6. Neuroimaging 
Computed tomography (CT) of a ganglioglioma or gangliocytoma may indicate a well-
circumscribed solid mass or cyst with a mural nodule and some calcification, and slight or 
absent contrast enhancement. Skull scalloping may be noted adjacent to superficial cerebral 
tumors. These lesions appear hypointense on T1-weighted and hyperintense on T2-
weighted magnetic resonance imaging (MRI), with well-defined masses showing 
enhancement absorption that can range from none to vivid and may be solid or only on the 
rim or nodular (13,14) . Figure 1 
 
Figure 1. MRI 
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3.7. Macroscopical features 
Gangliogliomas are solid or cystic lesions, characteristically with little mass effect. 
Calcification may be observed, whilst hemorrhage and necrosis are rare (8) 
3.8. Histopathology 
A primary characteristic of gangliogliomas is a mixture of neuronal and glial-cell elements 
that may display a striking heterogeneity. Gangliocytomas consist of clusters of large, 
multipolar neurons with immature features. The matrix contains non-neoplastic glial 
components and a network of reticulin fibers. Immature neurons are characterized by the 
loss of cyto-architectural arrangement of subcortical localization, a grouped appearance, 
enlargement of cells, and aggregation of Nissl bodies. Multinucleated neurons may present 
in 50% of cases. On the other hand, the glial element in gangliogliomas, which comprises the 
proliferation part of the tumor, shows considerable inconsistency, and may include any 
glial-cell type with Rosenthal fibers and eosinophilic granular bodies. Thestroma is typically 
fibrillary and may contain a microcystic component with mucous material. Occasional 
mitotic activity may be noted, and is typically compatible with the diagnosis of 
ganglioglioma, whereas necrosis is absent unless the glial component is undergoing 
malignant transformation. Other histopathological features that may be seen in 
gangliogliomas are calcifications, extensive lymphatic infiltrates with perivascular spaces or 
within the tumor substance or brain tissue, and a capillary network that forms an 
angiomatous constituent. In high-grade (anaplastic) gangliogliomas, malignant changes 
almost always involve the glial component and may be seen at the site of a previously 
removed ganglioglioma (2, 3, 5, 7, 8). Figure 2A 
3.9. Immunohistochemistry 
No specific marker is available to differentiate dysplastic and neoplastic neurons from 
normal and mature neurons. Neuronal protein markers, such as synaptophysin, 
neurofilaments, MAP2, and Neu N, are used to reveal the neuronal component in 
gangliogliomas.. However, use of the onco-fetal CD34 antigen can be positive, as CD34 is 
absent in neural cells of the adult brain but consistently expressed in 70% to 80% of 
gangliogliomas, especially those arising from the temporal lobe (15). Staining for GFAP 
reveals the astrocytic component the neoplastic glial element of gangliogliomas. Contrary to 
that seen in diffuse gliomas, MAP2 immunoreactivity is usually weak or absent in the 
astrocytic component of gangliogliomas (16). Figure 2B 
3.10. Electron microscopy 
The presence of neurons with dense core granules is a characteristic feature of 
gangliogliomas and gangliocytomas. Neuronal synaptic junctions may be few or completely 
absent (5,17). Observation of round protein bodies in gangliogliomas has also been 
mentioned (18). 
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Figure 2. A and B 
3.11. Proliferation index 
Ki-67/MIB-1 labeling the glial component has shown values ranging from 1.1 to 2.7%. 
Mitotic activity is low (5,7). 
3.12. Genetic susceptibility 
Genetic vulnerability to the development of gangliogliomas and gangliocytomas has not 
been well established. Previous studies reported a ganglioglioma of the optic nerve in a 
patient with neurofibromatosis type 1 (19) and a ganglioglioma in a Peutz-Jeghers patient 
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(20).. Mutational analysis of the tuberous sclerosis 1 (TSC1) and TSC2 genes revealed 
significant sequence alterations in the TSC2 gene, including polymorphisms in intron 4 and 
exon 41, in patients with gangliogliomas. In a further study of ezrin and radixin genes, 
coding for the interaction partners of TSC1 and TSC2 was not observed (30,31,32).  
Chromosomal abnormalities have been recorded in one-third of cases, in the approximately 
30 cases of gangliogliomas that have been studied cytogenetically, a change in chromosome 
7 was the most one observed. The karyotype was found to be abnormal in 3 cases with 
unfavorable outcomes. (21,22,23,24,25,26). Chromosomal imbalances have been detected in 
5/5 gangliogliomas by comparative genomic hybridization. Although partial loss of 
chromosome 9p and gain of chromosome 7 has been observed in several patients, abnormal 
epidermal growth factor receptor (EGFR) expression was not observed in these cases (27). A 
study of 14 cases (11 WHO grade I and 3 WHO grade III) failed to show TP53 mutation, 
PTEN mutation, or CDK4 and EGFR amplification, whereas CDKN2A deletion was 
observed in two-thirds of cases of anaplastic ganglioglioma (28). However, TP53 mutation 
was only noted in the recurrence of a WHO grade I ganglioglioma (29).  
3.13. Histogenesis 
The histogenesis of gangliogliomas and gangliocytomas still not understood. However, 
evolution from a dysplastic, abnormal glio-neuronal precursor with subsequent neoplastic 
transformation of the glial element has been proposed (33).  
3.14. Prognosic factors 
Favorable prognosis is observed in patients with long-standing epilepsy with temporal 
localization and complete surgical resectioning. These lesions are typically benign tumors 
with a 7.5-year recurrence-free survival rate of 94%.. Anaplastic changes, such as mitotic 
activity and microvascular proliferation and necrosis, in the glial component similar to those 
observed in high-grade gliomas.  
4. Central neurocytomas and extraventricular neurocytomas 
4.1. Definition 
Central neurocytomas and extraventricular neurocytomas are neoplasms composed of 
uniform round cells with neuronal differentiation. Central neurocytomas are typically 
located in the lateral ventricles in the region of the foramen of Monro and extraventricular 
neurocytomas in the brain parenchyma. These tumors are usually seen in young adults and 
have a favorable prognosis. 
4.2. WHO grading 
Central neurocytomas correspond histologically to WHO grade II tumors (1). 
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4.3. Historical background  
“Central neurocytoma” expression was used by Hassoun et al. (34) to describe a neuronal 
tumor with pathological features to differentiate it from cerebral neuroblastomas that occurs 
in young adults, it is commonly located in the third ventricle, and histologically may 
resemble oligodendrogliomas. They were also reported in other locations. The term central 
neurocytoma should be restricted to neoplasms located within the intracerebral ventricles. 
Tumors similar to central neurocytomas but occurring within the cerebral hemispheres 
(“cerebral neurocytomas”) or the spinal cord (35, 36,37) have subsequently been mentioned 
and described as “extraventricular neurocytoma” these tumours are now given to neoplasms 
that arise within the CNS parenchyma and have histological features with the more common 
central neurocytomas but exhibit a wider morphological spectrum. Neurocytic differentiation 
has been reported in an increasing number of tumors with specific morphological 
characteristics, some of these have been categorized as new entities, such as cerebellar 
liponeurocytomas, papillary glioneuronal tumors, or their variants (38, 39, 40). 
4.4. Incidence and sex distribution 
The incidence ranged from 0.25% to 0.5% of all intracranial tumors. In an analysis of 243 
cases, age at clinical manifestation is almost variable ranging from 8 days to 67 years (mean 
age, 29 years), with 69% between the ages of 20 and 40 year. Both sexes are equally affected 
(40, 34). 
4.5. Localization 
Central neurocytomas are usually located supratentorially in the lateral or the third 
ventricle. With most common site is the anterior part of the lateral ventricles (50%), more 
frequently on the left, followed by combined extension into the lateral and third ventricles 
and a bilateral intraventricular location. Attachment to the septum pellucidum is common, 
but isolated third-ventricular occurrence is rare. (40, 41) 
4.6. Clinical features 
The majority of patients present with symptoms of increased intracranial pressure rather 
than with other neurological deficit. The clinical history is short (mean 3.2 months). Central 
neurocytomas may present as acute hemorrhage or as an incidental finding on imaging (41). 
4.7. Neuroimaging 
On CT scans, mass is typically isodense or slightly hyperdense. Enhancement is common . 
Calcifications and cystic changes may be observed. MRI scan shows heterogeneous 
hypointensity on T1-weighted images and fluid- attenuated inversion recovery (FLAIR) and 
hyperintensity on T2-weighted images and FLAIR, with a well-defined margin mild to 
strong enhancement after gadolinum injection (42). Figure 3 
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Figure 3.  
4.8. Macroscopical appearance 
Intraventricular tumors are typically grey in color and friable with varying calcifications, 
these tumours are vascular and with occasional hemorrhage. ( 43,44) 
4.9. Histopathology 
Central neurocytomas have a benign histological appearance and may display  
various architectural patterns, even within the same specimen, including an 
oligodendroglioma-like honeycomb appearance, large fibrillary areas mimicking the 
irregular “rosettes” in pineocytomas. These lesions are neuroepithelial tumors composed 
of uniform round cells that show immunohistochemical and ultrastructural features of 
neuronal differentiation, fibrillary areas mimicking neuropils, and a low proliferation 
rate. Cells are isomorphous, having a round or oval nucleus with a finely speckled 
chromatin and an occasional nucleolus, cells arranged in straight lines, or perivascular 
pseudorosettes similar to those noted in ependymoma tumours. Calcifications are 
usually seen in around 50% of cases, normally distributed throughout the tumor. Blood 
vessels, classically arranged in a linear architecture pattern, giving an endocrine 
appearance. Rarer findings may include Homer Wright rosettes and ganglioid cells 
(43,44).  
These tumour may mimic, and must be distinguished from, oligodendroglioma, 
ependymoma, pineocytoma, and dysembryoplastic neuroepithelial . In rare cases, 
anaplastic histological features, including high mitotic activity and microvascular 
proliferation, have been observed. In some conditions, necrosis was associated with 
anaplastic features. Necrosis may also be observed in rare cases that are otherwise without 
malignant features, may be s as a vascular effect ( 41, 44, 46, 47, 48,49). Figure 4A 
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Figure 4. A and B 
4.10. Immunohistochemistry 
Synaptophysin is the most suitable and reliable diagnostic marker, with immunoreactivity 
diffusely present in neuropils, especially in fibrillary zones and perivascular nuclei-free 
cuffs (48). A significant number of nuclei are immunopositive for NeuN in almost all cases 
(50). The mean labeling index was 74% in one series of 11 cases, with a significantly lower 
Ki-67 staining rate for cells expressing NeuN (51). In extraventricular lesions, 
intracytoplasmic and para-nuclear immunolabeling must be cautiously inferred whenever 
other histological, immunohistochemical, or ultrastructural data of neuronal differentiation 
is lacking. Of particular interest is the anti-Hu antibody because it labels the nuclei of 
neurocytes (52). Chromogranin A and neurofilament staining are typically absent except 
when ganglion cells are present Although most studies found that GFAP was expressed 
only in trapped reactive astrocytes, the antigen has been detected by some studies in tumor 
cells ( 44, 45, 53 ,54). Figure 4B 
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4.11. Electron microscopy 
Electron microscopy may be required when expression of specific neuronal markers 
(synaptophysin, NeuN) is questionable and in other extraventricular neoplasms mimicking 
central neurocytomas. The central neurocytoma cells show uniform round nuclei with a 
finely discreted chromatin and a small nucleolus in a few cells. The cytoplasm contains 
mitochondria, a prominent Golgi apparatus, and several rough endoplasmic reticulum 
cisternae, often arranged in concentric lamellae. copious thin and combined cell processes 
containing microtubules and dense core and clear vesicles are always observed (41,55).  
4.12. Proliferation index  
MIB-1 labeling indices are classically low, usually less than 2%. However, Tumors with 
indices greater than 2%, as in one series in which they were found to be 3% , are referred to 
as “atypical neurocytomas” and associated with a significantly shorter recurrence-free 
interval (53, 56, 57). 
4.13. Genetic susceptibility 
Unclear, but central neurocytoma was observedin patients with von Hippel-Lindau disease 
(58). The molecular pathogenesis of central neurocytomas remains unknown, the 
observation of several genetic alterations, mainly chromosomal gains, has been reported. In 
one study, gain on chromosome 7 was observed in 3 of 9 neurocytomas (59). However, 
another study found no EGFR amplification in central neurocytomas (60). In related studies, 
gains on chromosomes 2p, 10q, 18q, and 13q were found in over 20% of tumors in one study 
; an isochromosome 17 and complex karyotype were observed in 2 studies (61, 62, 63); and 
TP53 mutations and MYCN amplification were reported to be rare or absent in several 
studies (45, 60, 63, 64, 65).there are two studies that reported loss of 1p and 19q, 1 study 
reported allelic loss on 1p as well as an inability to detect 19q (64), whereas the other study 
reported 6 of 9 tumors showed loss at 1 or more loci on 1p and that 5 tumors showed 19q 
loss. These data suggest that central neurocytomas are genetically distinct from 
oligodendrogliomas. Although the expression profiles of cerebellar liponeurocytomas 
appear to have a closer relationship to those of central neurocytomas, the lack of TP53 
mutations in central neurocytomas suggests the involvement of different genetic pathways 
(60, 66,67). 
4.14. Histogenesis 
Central neurocytomas were previously thought to be derived from precurssor cells of the 
septum pellucidum (34). Still, the indication of both astrocytic and neuronal differentiation 
in some tumor cells by various approaches in vivo and in vitro has suggested that they are 
derived from neuroglial precursor cells with a potential to undergo dual differentiation. 
These precursor cells might arise from the subependymal layer of the lateral ventricle or 
from the ventricular region. (45,54, 68). 
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4.15. Prognostic factors 
The natural course of central neurocytoma is classically benign. Total surgical resection is 
the most important prognostic factor. recurrence is frequent with incomplete removal, but 
the residual tumor growth can be treated with radiotherapy. CNS dissemination is rare. (57, 
66, 69, 70). central neurocytomas is rarely aggressive (44,47). Patients with central 
neurocytomas and a MIB-1 labeling index (LI) >2% or >3% have significantly shorter 
recurrence-free intervals. Involvement of the periventricular parenchyma involvement may 
be associated with poor outcome ( 71, 72). 
4.16. Extraventricular neurocytomas 
Extraventricular neurocytomas are usually well-defined and contrast-enhancing lesions that 
often have a cyst–mural nodule complex which is usually useful in distinguishing them 
from histologically similar neoplasms, such as oligodendrogliomas. Histologically, 
extraventricular neurocytomas may be identical to central lesions, but are often more 
complex, less cellular, and more likely to contain ganglion cells or ganglioid cells with nuclei 
that are larger than those of neurocytes. Lower cellularity, in combination with the presence 
of perinuclear haloes, may give these lesions the appearance of oligodendrogliomas. 
Although GFAP-positive glial cells have been observed, it has been difficult to identify them 
as clearly neoplastic. Hyalinized vessels and dense calcification are common (73). 
5. Dysembryoplastic neuroepithelial tumors  
5.1. Definition 
Dysembryoplastic neuroepithelial tumors (DNTs) are usually benign. They are supratentorial 
glio- neuronal neoplasms that seen in children or young adults. Characterized by a cortical 
location and intractable partial complex seizures, they ideally demonstrate a complex columnar 
and multinodular structural design and are often associated with cortical dysplasia (74). 
5.2. WHO grading 
DNTs correspond histologically to WHO grade I tumors. (1) 
5.3. Historical background 
DNTs were first recognized as lesions in patients who had undergone epilepsy surgery for the 
treatment of longstanding, drug-resistant partial seizure sand showed unusual morphological 
features, including cortical topography, multinodular architecture, a “specific glioneuronal 
component” with a columnar structure. No recurrence with long term follow up even in 
patients with incomplete partia resection. Several factors strongly suggested a dysembryoplastic 
origin, the term “dysembryoplastic neuroepithelial tumor” was proposed for these lesions (74).  
In the 1993 WHO Classification of Tumors Affecting the Central Nervous System (36), DNTs 
were included in the category of “neuronal and mixed neuronal-glial tumors.” With 
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“complex form,” and “simple type” (75). Later , “non-specific histological forms” were 
addedd. Furthermore, it has been indicated that DNTs may be seen in the infratentorial 
location (76, 77, 78,79). 
5.4. Incidence 
Incidence is variable. In a study of patients who were treated surgically for epilepsy, the 
incidence of “typical” DNTs was reported to be 12% in adults and 13.5% in children (80), 
whereas it was reported to be 19% to 22% in all patients in a series that included “non-
specific” histological variants (78,81,82). Among all neuroepithelial tumors diagnosed in a 
single institution, DNTs were identified in about 0.2% among patients aged more than 20 
years and in 1.2% of the patients under the age of 20 years (83). 
5.5. Age and sex distribution 
In about 90% of cases, the first seizure attack occurs before 20 years of age, but it may 
present from 3 weeks to 38 years (84,85). though patients are often diagnosed in the 2ed or 
3rd decade of life, detection of DNTs by imaging in children or young adults with recent 
onset seizures has become more common, leading to more surgical intervention for 
treatment of DNTs in pediatric neurosurgery. It was observe that males are more slightly 
affected. (86, 87, 88, 89,90).  
5.6. Localization 
There is a predilection for the temporal lobe and for involvement with mesial structures 
although DNTs may be located in any part of the supratentorial cortex, (80, 81,82,83,84). In 
one series of patients treated in a general practice, temporal lobe involvement was found in 
50% or fewer of cases (85,86). DNTs have also been found in the area of the caudate nucleus 
(76,77) or lateral ventricle, the septum pellucidum, the trigonoseptal region (88), the 
midbrain and tectum , and the cerebellum or cerebellum and brain stem (89,90,91,92). In 
total, 25 extracortical cases have been reported. In addition, 4 cases of multifocal DNTs have 
been reported, indicating that these tumors may arise in the region of the third ventricle, the 
basal ganglia, and the pons (93, 94,95). 
5.7. Clinical presentation  
Drug -resistant partial complex seizure is the typical presentation with or without secondary 
generalization, and no focal neurological deficit. The duration of seizures prior to surgical 
resection can vary from weeks to many years, leading to variability in patient age at 
pathologic diagnosis(79, 73,74, 97,98). 
5.8. Neuroimaging 
The cortical location of the lesion in the absence of both mass effect and peritumoral edema are 
important criteria in differentiating between DNTs and gliomas. DNTs typically encompass 
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the thickness of the normal cortex and, in a minority of the cases, have an area of signal 
abnormality that extends into the subcortical white matter. The cortical location of the lesion is 
easily identified on MRI than on CT. DNTs appear hyperintense on T2-weighted images and 
hypointense or iso-intense on T1-weighted images. They often have a pseudo-cystic or multi-
cystic appearance although true cyst formations are rare and small (91). In tumors located at 
the convexity, scalloping of the overlying bone is often observed on scans , a finding supports 
the diagnosis of DNT(, 77, 99,100, 101,102). Calcifications are rare. Contrast enhancement on 
CT or MRI is not common, it is often appearing as rings rather than homogeneous 
enhancement. Such ring-shaped contrast enhancement may be observed on a previously non-
enhancing tumor on scans (96, 102). Increased tumour size, without peritumoral edema, may 
also be observed on imaging follow-up. However, these changes are naturally not signs of 
malignant transformation but rather as a result of ischemic or hemorrhagic changes (103,104). 
5.9. Macroscopy 
DNTs vary in size from several millimeters to several centimeters. In their typical location, 
they are often easily identified superficially at the cortical, and may show exophytic 
development, but indicate no involvement of leptomeninges. The most typical feature is 
viscous consistency of the glioneuronal component, which may be associated with multiple 
or single firmer nodules, and spreading out of the affected cortex (68). 
5.10. Histopathology 
The histological hallmark of a classical DNT is the presence of a “specific glio-neuronal 
constituent.” This element is characterized by columns formed by bundles of axons lined by 
small oligodendroglia-like cells that are oriented perpendicularly to the cortical surface 
between which neurons with normal cytology appear to float in a pale, eosinophilic 
medium. There are also elements of scattered GFAP-positive stellate astrocytes. Depending 
on the amount of fluid extravasation, subtle variation from a columnar to o a more packed 
in structure may be observed . Several histological forms of DNTs have been mentioned, but 
their subclassification has no clinical or therapeutic implications (76,77). Figure 5A.B 
5.11. Complex and non specific forms 
In the complex form of a DNT, glial nodules, which give the tumor a feature of 
multinodular pattern, are seen in association with a specific glio-neuronal element. The 
variable appearance of these tumors is due to the presence of multiple cells of astrocytic, 
oligodendrocytic, and neuronal components. The glial components seen in the complex 
forms of DNTs have a highly variable form due to many causes : 1- they may form typical 
nodules with diffuse pattern; 2- they may mimic usual categories of gliomas and may 
illustrate unusual features; 3- they usually resemble low-grade gliomas, but may 
demonstrate nuclear atypia, some mitotic activity, or microvascular-like proliferation and 
ischemic necrosis; 4- they display a microvascular network. Within the glial components, 
typically calcified vessels are frequent that may behave as vascular malformations and be 
responsible for bleeding (65,66,86, 99,101,103, 104,105).  
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Figure 5. A and B 
“Non-specific” histological variants of DNTs, identified according to clinical presentation as 
well as their cortical location, neuroimaging features, and steadiness on long-term 
preoperative imaging follow-up, have been described (77). Due to lackness the specific 
glioneuronal element and multinodular architecture, these variants are often histologically 
indistinguishable from low-grade gliomas. The diagnosis of these tumors thus requires that 
the clinical presentation and neuro-imaging appearance of the lesion be taken into 
consideration. Non-specific histological types account for 20% to 50% of DNTs in many 
studies (79,106,). Although gliomas identified in patients with long-term epilepsy during 
epilepsy surgery are typically associated with a distinctly benign course the diagnosis of 
“non-specific” histological variants of DNTs still debatable ( 107,108,110). 
5.12. Simple form 
Morphologically, the simple form of a DNT consists of a unique glioneuronal component it 
shows a patchy pattern owing to the proximity of foci of tumor and a well-defined cortex (76),. 
5.13. Cortical dysplasia and Neuronal distribution of DNTs 
Dysplastic disorganization of the cortex has been observed in up to 80% of DNT cases in studies 
with adequate sampling (111,112). Supratentorial cortical DNTs contain mature neurons that, 
both in the tumor itself and in the area of cortical dysplasia, may show different degrees of 
cytological anomaly. Thoug, DNTs do not have atypical or immature neurons that look like 
dysplastic ganglion cells as observed in gangliogliomas. Some tumor cells with an 
oligodendrocytic appearance have been found to occasionally express neuronal markers and 
display axo-somatic synapses suggesting that what is called “oligodendroglial-like cells” of 
DNTs and it may undergo early neuronal differentiation. However, using in-situ hybridization 
indicates that oligodendro-glial-like cells copy myelin genes and express myelin oligodendrocyte 
glycoprotein protein, indicating oligodendro-glial demarcation (113, 114,115, 116). 
5.14. Cortical topography 
The borders of the tumor often match with those of the cortex to a very large degree. it also 
appears to involve the adjoining white matter. However, as neurons are typically found in 
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even the deeper parts of the tumor and in the neighboring white matter, such association is 
high likely indicates disordered neuronal migration (117). 
5.15. Diagnostic criteria 
The diagnosis of DNT should be taken into consideration in every case in which all of the 
following criteria (76, 77, 80. 81) are present:  
1. the presence of partial complex seizures with/ without secondary generalization 
beginning before age 20  
2. the absence of progressive neurological deficit. 
3. the presence of a supratentorial lesion with a predominantly cortical topography, best 
indicated on MRI 
4. the absence of mass effect on CT or MRI, except if related to a cyst 
5. the absence of peritumoral edema on the scans 
5.16. Comparison between DNTs and gangliogliomas 
Differential diagnosis of DNTs and gangliogliomas may be tricky on account of several 
factors: 1- the clinical presentation of gangliogliomas is often similar to that of DNTs. 2- the 
immature ganglion cells of gangliogliomas may not be present in a small or inadequate 
sample. 3- Gangliogliomas may show a multinodular arrangement, 4- small gangliogliomas 
may show a predominant cortical topography. 
A ganglioglioma is suspected when a tumor shows perivascular lymphocytic infiltration, a 
network of reticulin fibers, and a large cystic component. as gangliogliomas may undergo 
malignant transformation, their distinction from DNTs is important from a prognostic point 
of view. ( 118, 119, 120,121). 
5.17. Comparison between DNTs and low-grade gliomas 
The above clinical and radiological criteria help in distinguishing benign DNTs from diffuse 
gliomas. In diagnosis, it is important to consider that 1- in diffuse gliomas, so-called 
“floating” neurons may be present, 2- in low-grade diffuse gliomas, infiltrative microcystic 
activity may cause to the formation of a construction that mimics a “specific glio-neuronal 
element”; 3- some oligodendrogliomas, a nodular pattern may be seen, 4- in diffuse gliomas, 
secondary architectural changes in the cortex caused by the expansion of gliomas into the 
cortex may be not easy to differentiate from the presence of dysplastic cortical 
disorganization (76,77,80.81).. 
5.18. Genetic susceptibility 
DNTs have reported in patients with neurofibromatosis type 1 (NF1) and with XYY 
syndrome (122,123,124). 
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5.19. Proliferation index  
Variable MIB-1 labeling indices of DNTs have been reported from 0% to 8% focally (79, 81, 
84). 
5.20. Histogenesis 
Many factors have suggested that DNTs are a malformative origin, including the presence of 
focal cortical dysplasia and migrated neurons in the adjacent white matter, young age of 
symptom onset, and bone deformity adjacent to the tumor. Some observations indicate that 
they may be derived from secondary germinal layers. the histogenesis of DNTs remains 
unknown (74,77,81, 125) 
5.21. Prognostic factors 
DNTs are benign lesions. Their stability was indicated in a study of 53 patients for whom 
successive pre-operative CT or MRI was available with a mean duration of follow-up of 4.5 
years (102). Long-term clinical follow-up typically shows no evidence of recurrence, even in 
patients with incomplete surgical resection ( 76, 97,99, 102, 107, 126). Risk factors for post 
operative recurrent seizures at long-term follow-up include longer pre-operative history of 
seizures, cortical dysplasia next to DNT and residual tumour ( 85, 100, 127, 128). Malignant 
transformation is extremely rare, only 2 cases reported from 700 cases of DNTs (129).  
6. Desmoplastic infantile astrocytomas and desmoplastic infantile 
gangliogliomas 
Desmoplastic infantile astrocytomas (DIAs) and desmoplastic infantile gangliogliomas (DIGs) 
are usually large cystic tumors occurring in infantile period that typically affect the cerebral 
cortex and leptomeninges and are often attached to the dura. DIGs contain neoplastic 
astrocytes and neuronal components while DIAs contain only neoplastic astrocytes. 
6.1. WHO grading 
Histologically, DIAs and DIGs correspond to WHO grade I tumors. 
6.2. Historical annotation  
DIAs were originally described by Taratuto et al in 1982. (130) as meningocerebral 
astrocytomas attached to the dura displaying a desmoplastic reaction. Their subsequent 
description as superficial cerebral astrocytomas attached to the dura (131) led to the 
delineation of a previously unknown entity. In 1993, this entity was included in the WHO 
Classification of Tumors Affecting the Central Nervous System (132) under the term 
“desmoplastic cerebral astrocytoma of infancy.” In 1987, VandenBerg et al reported 
observation of desmoplastic supratentorial neuroepithelial tumors of infancy with diverse 
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differentiation (“desmoplastic infantile gangliogliomas”) in the same clinical setting. They 
described the histopathology of DIGs as differing from that of DIAs due to the presence of a 
neuronal component with variable differentiation in the former. (133). Since both types of 
lesions have similar clinical and neuroimaging features they have been currently 
categorized together as DIAs or DIGs in the WHO Classification. 
6.3. Incidence 
DIAs and DIGs are rare tumours and only observed in childhood whose rate can only be 
estimated from their reported frequency in institutional series. One series of 6500 CNS 
tumors in patients of all ages reported only 22 cases of DIG at a rate of 0.3% (134). In a series 
of CNS intracranial tumors limited only to the pediatric age group reported 6 cases of DIA, 
accounting for 1.25% of all childhood brain neoplasm. While, reports limited to brain tumors 
of infancy have found that DIAs and DIGs account for 16% of intracranial tumors (131,135).  
6.4. Age and sex allocation 
In a study, the age range for 84 reported cases of DIA and DIG was found to be 1 to 24 
months. Males ae more commonly affected, with Male:female ratio is 1.5:1. The large 
majority of infantile cases present within the first year of life. However, several non-infantile 
DIA, DIG between 5 to 25 years have been reported (136, 137). 
6.5. Localization 
DIAs and DIGs invariably arise in the supratentorial region and commonly involve more 
than one lobe, most frequently the frontal and parietal lobes, followed by the temporal and 
less commom the occipital lobe (137). 
6.6. Clinical presentation  
The clinical features of DIAs and DIGs are of short duration and include increasing head 
circumference, tense and bulging fontanelles, lethargy, and sun set sign. Patients may also 
present with seizuresor focal motor signs, calvarial bulging over the tumor may also be 
observed (136). 
6.7. Neuroimaging 
On CT, these lesions are seen as large, hypodense cystic masses with a solid isodense or 
slightly hyperdense superficial portion that extends into the overlying meninges and shows 
contrast enhancement. The cystic portion is typically located deep within the tumor, where 
the solid portion is peripheral. The MRI T1-weighted images are characterized by a 
hypointense cystic component with an isointense peripheral solid component that takes 
contrast. On T2-weighted images, the cystic component is hyperintense and the solid 
portion is heterogeneous. Edema is usually absent or light (138). Figure 6 
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Figure 6. A and B 
6.8. Macroscopy 
DIAs and DIGs are typically large tumors, measuring up to 13 cm in diameter, with deep 
multiloculated cysts filled with clear or xanthochromic fluid. The solid superficial portion is 
primarily extracerebral, attached to leptomeninges and the superficial cortex, it is firm or 
rubbery in consistency, and grey or white in color.  
6.9. Histopathology 
The DIA or DIG composed of neuroepithelial tumor with 3 characteristic components: a main 
desmoplastic leptomeningeal component, a poorly differentiated neuroepithelial component, 
and a cortical component. The desmoplastic leptomeningeal component consists of a mixture of 
fibroblast-like spindle-shaped cells and pleomorphic, neoplastic, and neuroepithelial cells with 
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eosinophilic cytoplasm, both of which are arranged in fascicles or in a whorled pattern. Reticulin 
impregnations show a prominent reticulin-positive network surrounding almost every cell and 
mimicking that of a mesenchymal tumor. Astrocytes are the main tumor-cell feature in DIAs or 
the predominant neoplastic population associated with immature neurons in DIGs. The type of 
neoplastic neuron may range from atypical ganglionic cell to a small polygonal cell (133,139). 
In addition to this desmoplastic leptomeningeal component, both DIAs and DIGs contain a 
group of poorly differentiated neuroepithelial cells with small, round, deeply basophilic 
nuclei and minimal surrounding perikarya. Such an immature component lacking 
desmoplasia may predominate in some areas. A cortical component devoid of desmoplasia 
may also be seen that is often multinodular, with some nodules being microcystic 
(139).There is a sharp delineation between the cortical surface and the desmoplastic 
neoplasm, Virchow-Robin spaces in the underlying cortex are often occupied with tumor 
cells. Calcifications are frequent. Mitotic activity and necrosis are rare. Some tumors may be 
slightly vascular (137, 140, 141, 142). Figure 7A.B 
 
Figure 7.  
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6.10. Immunohistochemistry 
In the desmoplastic leptomeningeal component, fibroblast-like cells express vimentin. As 
most other neuroepithelial tumor cells react with GFAP, astrocytes predominate in this 
component. Antibodies to collagen typr VI react in a reticulin-like pattern around tumor 
cells (143,144). Expression of neuronal markers (synaptophysin, NF-H, and class III ß-
tubulin) has been observed in both the neoplastic neuronal cells as well as cells lacking 
apparent neuronal differentiation (145). In the poorly differentiated neuroepithelial 
component, cells react with not only GFAP and vimentin but also with neuronal markers 
and MAP2 Desmin expression may be present (134,145, 146, 148); but epithelial markers 
(CAM 5.2, AE1/AE3, and EMA) are usually absent (145). Figure 8A.B 
6.11. Electron microscopy 
Astrocytic tumor cells are characterized by intermediate filaments typically arranged in 
bundles as well as scattered cisternae of rough endoplasmic reticulum and mitochondria 
with extensive basal lamina. Fibroblasts containing granular endoplasmic reticulum and 
well-developed Golgi complexes (141, 142). The neuronal cells of DIGs contain dense core 
secretory granules and neurofilaments. Immunoelectron microscopy has shown filamentous 
reactivity to NF-H in these neuronal cell bodies as well as processes lacking involvement of 
the basal lamina. (149). 
6.12. Proliferation index  
Mitotic activity is rare and, when present, is mostly restricted to the undifferentiated, small-
cells in DIGs (134,139). Ki-67 labeling indices reported in the literature range from less than 
0.5% to 5%, with the majority of studies reporting them as less than 2% (150). Proliferation 
does not appear to be related to clinical behavior in completely resected tumors but may 
expect more aggressive nature in subtotally resected cases. In 3 cases analyzed by flow 
cytometry, the S-phase fraction ranged from 3.7% to 12%, with a mean of 6.6% (151, 152, 
153). 
6.13. Histogenesis 
The cellular origins of DIAs and DIGs is yet to be known. The presence of primitive small-
cell populations that express both glial and neuronal proteins suggest that these cells are 
progenitor cells to the more differentiated neuroepithelial components and supports the 
contention that DIAs and DIGs are embryonal neoplasms programmed to progressive 
maturation (42,155). Origination from the specialized subpial astrocytes that form a 
continuous, limiting basal lamina providing their terminal processes could account for a 
comparable phenomenon occurring in desmoplastic infantile tumors and for their 
superficial localization. The lack of genetic alterationsas observed in most diffuse 
astrocytomas suggests they are not related to these neoplasms (142,143). 
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Figure 8. A and B 
6.14. Genetics susceptibility 
A comparative genomic hybridization study of 3 cases of DIA and DIG revealed no 
consistent chromosomal gains or losses (150). Molecular studies of DIAs revealed no loss of 
heterozygosity on chromosomes 10 and 17 and the absence of TP53 mutations (142,152). One 
 
Neuronal and Mixed Neuronal-Glial Tumors of the Central Nervous System 217 
case of DIG showed a loss on 8p22-pter, whereas one case of DIA showed a gain on 13q21. 
(154). 
6.15. Prognostic factors and outcome 
Follow-up studies indicate that gross total removal is the treatment of choice. In a study 14 
of patients with DIGs (median follow-up, 8.7 years), no mortality or evidence of tumor 
recurrence was observed (134).. In cases of subtotal resectioning or biopsy, most tumors are 
stable or recurre slowly. In 1 study, 2 tumors showed radiologic evidence of tumor 
regression following incomplete resectioning . Dissemination of these tumors through the 
CSF has been reported but rare,(151,156) Long-term tumor control in cases of DIA and DIG 
can be achieved by total surgical resectioning despite the presence of primitive-appearing 
cellular aggregates with mitotic activity or foci of necrosis.. However, tumor evolution has 
been reported in cases of DIG that underwent subtotal removal , including those with high 
proliferative indices and anaplastic features (149,157,158) 
7. Rosette-forming glioneuronal tumor of the fourth ventricle 
7.1. Definition 
This type of posterior fossa tumours is a rare and slowly growing neoplasm in the fourth 
ventricular region, predominantly affecting young adults, and composed of uniform 
neurocytes forming rosettes or perivascular pseudorosettes and astrocytes mimic pilocytic 
astrocytoma. 
7.2. Grading 
The rosette-forming glioneuronal tumor (RGNT) corresponds to WHO grade I (1). 
7.3. Synonyms  
A neoplasm displaying features of RGNT was early reported as a “dysembryoplastic 
neuroepithelial tumor (DNT) of the cerebellum” . However, Komori et al. described RGNT 
as a distinct entity as a variant of mixed glio-neuronal tumor (159,160). Wheares, Preusser et 
al. confirmed RGNT as a tumor entity (161). 
7.4. Age and sex distribution 
The age range at disease presentation is 12–59 years (mean, 33 years). With a slight female 
preference. 
7.5. Incidence and localization 
RGNT is a rare brain tumor. In five different studies, only 17 cases were reported. These 
lesions arise in the midline and occupy the fourth ventricle and may be the aqueduct, it may 
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extend to involve the adjacent brain stem, cerebellar vermis, pineal gland, or thalamus( 
160,161, 163, 164,165).  
7.6. Neuroimaging  
MR imaging reveals a relatively circumscribed, solid tumor in the fourth ventricular region, 
showing low intensity on T1-weighted images and high intensity on T2-weighted images, , 
and focal or heterogenous gadolinium enhancement. Secondary hydrocephalus is common ( 
164,165) . 
7.7. Clinical features 
The clinical presentation of RGNT is most often with headache due to of obstructive 
hydrocephalus, and unsteadiness. Cervical pain is occasionally experienced. Rarely 
discovered incidentally. Figure 9. 
 
Figure 9.  
7.8. Histopathology 
RGNTs are well demarcated, but some infiltration into the brain stem and cerebellar 
parenchyma may be observed. They are characterized by a biphasic neurocytic and glial 
architecture. The neurocytic component consists of a uniform group of neurocytes. these 
cells have spherical nuclei with finely granular chromatin, inconspicuous nucleoli, scant 
cytoplasm, and delicate cytoplasmic processes forming neurocytic rosettes and/or 
perivascular pseudorosettes. Neurocytic rosettes feature ring-like arrays of neurocytic nuclei 
surrounding delicate eosinophilic neuropil cores. While the perivascular pseudorosettes 
feature delicate cell processes radiating toward vessels. The neurocytic rosettes and 
perivascular pseudorosettes when viewed longitudinally, may show a columnar 
arrangement.. These neurocytic structures may lie in a partly microcystic, mucinous matrix. 
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The glial component of RGNT typically dominates, and in some areas may resemble 
pilocytic astrocytoma. Astrocytic tumor cells are spindle to stellate in shape, with elongated 
to oval nuclei and moderately dense chromatin. Cytoplasmic processes often form a 
compact to loosely textured fibrillary background. Rosenthal fibers, eosinophilic granular 
bodies, microcalcifications, and hemosiderin deposits may be observed. In some areas, the 
glial component may be microcystic, containing round, oligodendroglia-like cells with some 
perinuclear halos. Vessels may be thin-walled and dilated or hyalinized. Thrombosed 
vessels and glomeruloid vasculature may also be noted. The adjacent cerebellar cortex has 
no features of dysplasia ( 160,162, 164, 165). Figure 10A 
 
Figure 10. A and B 
7.9. Immunohistochemistry 
Immunoreactivity for synaptophysin is present at the centers of neurocytic rosettes and in 
the neuropil of perivascular pseudorosettes.furthermore, the cytoplasm and processes of 
neurocytic tumor cells may express MAP-2 and neuron-specific enolase. GFAP and S-100 
immunoreactivity is shown in the glial part, but absent in the rosettes and pseudorosettes. 
(160, 162, 164). Figure 10 B. 
7.10. Proliferation index  
Ki-67 labeling indices are low, being less than 3% in reported cases, Mitosis is absent (165). 
7.11. Genetic susceptibility 
One reported patient with RGNT had a Chiari type I malformation (160). No other evidence 
of an underlying neurological disorder or association with a familial tumor syndrome has 
been reported. 
7.12. Histogenesis 
The histological investigations indicate that RGNTs arise from the brain tissue surrounding 
the infratentorial ventricular system. An origin of RGNT from the subependymal plate; the 
remnants of the periventricular germinal matrix has been suggested (160). 
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7.13. Outcome  
The clinical outcome of these primary benign neoplasm is favorable in terms of survival, but 
disabling cerebellar features postoperatively have been reported in approximately half the 
cases (160). 
8. Papillary glio-neuronal tumor 
8.1. Definition 
A well circumscribed, clinically insidius and histologically biphasic cerebral neoplasm 
composed of flat to cuboidal, GFAP-positive astrocytes lining hyalinized vascular 
pseudopapillae and synaptophysin-positive interpapillary collections of sheets of 
neurocytes, large neurons, and ganglioid cells. 
8.2. Grading 
Papillary glioneuronal tumors is corresponding to WHO grade I. late aggressive behavior 
has been reported (1,165). 
8.3. Historical annotation 
The papillary glioneuronal tumor, was first established as a distinct clinicopathological 
entity by Komori et al. in 1998 and listed in the 2000 WHO classification as a variant of 
ganglioglioma, (166). Some tumors were previously described under a variety of names, 
including pseudopapillary ganglioglioneurocytoma and pseudopapillary neurocytoma with 
glial differentiation ( 167,168). 
8.4. Incidence, age and sex distribution 
They are very rare neoplasms; and only a few cases have been reported (169.170). These 
tumors may occur at any age. There is no gender preference. The mean age at presentation is 
27 years; the oldest and youngest patient reported was 75 and 4 years, respectively 
(171,172).. 
8.5. Localization 
These tumors are generally seen in the cerebral hemispheres, with a predilection for the 
temporal lobe. 
8.6. Neuroimaging 
On MRI and CT imaging, the tumors appear as well defined, solid and/ or cystic, with some 
contrast-enhancement there is usually little mass effect. A cyst-mural nodule architecture 
may be observed (166, 169.173). 
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8.7. Clinical features 
Mainly headache and seizures. Focal deficits, cognition, and emotional disorder may also be 
encountered. (174). 
8.8. Histopathology and immunohistochemistry 
Papillary glioneuronal neoplasms is characterized by a prominent pseudopapillary manner 
in which a single or pseudostratified layer of small, cuboidal glial cells with rounded nuclei 
and scant cytoplasm covers hyalinized blood vessels, as well as interpapillary sheets or focal 
collections of neurocytes, and occasionally ganglion cells or medium-sized ganglioid cells 
with accompanying neuropil.  
At the immunohistochemical level, vessels with mural hyalinization are ensheathed by a 
layer of small, uniform, GFAP-positive cells with rounded nuclei and scant cytoplasm. In 
some cases, OLIG2-positive, GFAP-negative glial cells surround this layer. These glial 
elements lack both nuclear atypia and mitotic activity. Interpapillary neuronal elements 
show considerable variation in size and shape. all get stained with antisera to 
synaptophysin, NSE, and class III-tubulin. The majority of neuronal cells are positive for 
NeuN, but NFP expression is mostly confined to larger ganglioid and ganglion cells. 
Membranous immunoreactivity for NCAM is also found ( 166, 172, 175), but chromogranin-
A expression is lacking. Minigemistocytes which show intense GFAP immunoreactivity, are 
occasionally noted in the interpapillary spaces. Microvascular proliferation or necrosis is 
rare. Even in cases with increased proliferative activity. At the periphery of the lesion, 
scattered tumor cells are mixed with gliotic brain tissue containing Rosenthal fibers, 
eosinophilic granular bodies, hemosiderin, and microcalcifications are encountered; this 
results in a a blurred tumor edge ( 165, 175). Figure 11 A.B 
8.9. Electron microscopy 
The ultrastructure of few papillary glioneuronal tumors has been studied. Three cell types 
have been reported: astrocytic; neuronal; and poorly differentiated neurons. Neurons vary 
in size: large forms with abundant organelles lie between the papillae; their neuronal 
processes filled with parallel microtubules showed terminations containing clear vesicles 
and occasional synapses. The poorly differentiated cells contain mitochondria, ribosomes, 
occasional dense bodies, intermediate filaments and microtubules, but no well-formed 
dense core granules. Astrocytes contain bundles of intermediate filaments, and are 
separated from vessels by a basal lamina. Minigemistocytes and OLIG-2-expressing 
oligodendrocyte-like cells may also be present ( 165, 166, 171). 
8.10. Proliferation index  
MIB-1 labeling indices are usually low, in the range of 1–2%. Only 1 tumor featuring 
minigemistocytes showed an increased (10%) labeling index in that unusual element (165). 
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Figure 11. A and B 
8.11. Genetic susceptibility 
Papillary glioneuronal tumors reported to date have been sporadic in occurrence. (175). 
8.12. Histogenesis 
The histogenesis of papillary glioneuronal tumors is uncertain, but an origin from 
multipotent precursors capable of divergent glioneuronal differentiation is supposed. 
(166). 
8.13. Prognosis  
The cystic formation, indolent course and low proliferative activity are given a favorable 
clinical outcome. In most cases, gross total resection without adjuvant therapy is curable 
with long-term survival. (165). 
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9. Cerebellar liponeurocytoma 
9.1. Definition 
A very rare cerebellar neoplasm with variable neuronal, astrocytic, and focal lipomatous 
differentiation, and low proliferative potential; the tumor usually has a favorable clinical 
course. 
9.2. Grading 
Data available advocate that this tumor typically corresponded to WHO grade I (1). 
However, recurrences have been reported in almost 50% cases, typically without the 
histological features of malignant transformation. (176).  
9.3. Synonyms and historical annotation 
Bechtel et al. Reported a case of lipomatous medulloblastoma in a 44-year-old man. in 1978 
(177). Subsequently 28 more cases were reported. The terms neurolipocytoma (178), 
medullocytoma (179), lipomatous glioneurocytoma (180), and lipidized mature 
neuroectodermal tumor of the cerebellum (181). The WHO Classification in 2000 (1) 
included the term “cerebellar liponeurocytoma”. However, This term is now widely 
accepted, and is supported by genetic analyses indicating that this lesion is not a variant of 
medulloblastoma (170). Clinical, histopathological, immunohistochemical, and genetic data 
strongly suggest that the cerebellar liponeurocytoma comprise a rare but distinct clinico-
pathological entity. Some tumors with features of liponeurocytoma have also been observed 
in supratentorial locations. (182, 183, 184).. 
9.4. Age and sex distribution 
In the 29 patients with cerebellar liponeurocytoma reported ( 182, 185, 186, 187,188,189), the 
mean age was around 50 years (range, 24–77 years), with a peak in the third to sixth decade 
of life. This is in contrast with the age distribution of cerebellar medulloblastomas, more 
than 70% of which occur in children (178). There is no significant gender predilection (13 
men and 16 women) in patients with cerebellar Liponeurocytoma (186, 187,188,189). 
9.5. Clinical features 
Non specific symptoms such as Headache and signs of raised intracranial pressure may be 
the initial presentation, resulting from either the lesion itself or obstructive hydrocephalus. 
Cerebellar signs are also frequent (188). 
9.6. Neuroimaging 
MRI appearance is variable, and may be related to the distribution and proportion of 
lipidized tissue. On T1-weighted MRI, the mass is generally hyperintense but 
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heterogeneous. Hyperintense streaks on T2-weighted images have been associated with the 
macroscopic appearance of adipose tissue at surgery. Enhancement with gadolinium is 
usually irregular. Peritumoral edema is usually absent (,190, 191). 
9.7. Localization 
These neoplasms are predominantly located in the cerebellar hemispheres, followed by in 
the vermis. And rarely in the cerebellopontine angle. Raely, liponeurocytomas have been 
diagnosed in the supratentorial ventricular system at a rate to approximately 3% of central 
neurocytomas. There are 2 cases of cerebellar neurocytomas without adipose tissue have 
been reported ( 182, 185, 192, 193). In 1 case, it was shown that the lipid vacuoles 
progressively accumulate and coalesce within cells, maintaining neurocytic features, and 
indicating tumoral lipidization rather than true adipose metaplasia. These observations 
justify the description of central liponeurocytoma as a separate entity, and these lesions 
contribute to histogenetic and biological characteristics with cerebellar liponeurocytoma 
(194, 195,196). 
9.8. Histopathology 
Biphasic in appearance, the tumor consists of small neuronal cells with the cytology of 
neurocytes and focal lipomatous differentiation, characterized by lipidized cells resembling 
mature adipose tissue. Tumor cells have round or oval nuclei, and often show a clear 
cytoplasm resembling neoplastic oligodendrocytes, but also have many morphological 
similarities to medulloblastoma and clear cell ependymoma. Despite the cellularity of the 
lesion, tumor cells have a uniform cytological appearance, with absent or very few mitotic 
figures and aggressive features. No malignant transformation noted (194, 195,196). Figure 
12A 
9.9. Immunohistochemistry 
Neuronal differentiation is observed by a reliable, diffuse expression of NSE, synaptophysin, 
and MAP-2. Accordingly, several reported cases were diagnosed as neurocytoma or 
neuroblastoma, rather than medulloblastoma. Focal GFAP expression by tumor is also seen, 
indicating astrocytic differentiation (184). Immunoreactivity for neuronal markers and GFAP 
is also seen in the adipose cells, indicating an abnormal differentiation of tumor cells rather 
than an entrapped adipocytes. It is crucial to note that xanthomatous histiocytes, as are 
occasionally observed in ordinary medulloblastomas, are not considered evidence of 
lipomatous differentiation. Two reports mention additional immunoreactivity to desmin, and 
morphological features of incipient myogenic differentiation (177,181). Figure 12 B 
9.10. Differential diagnosis 
The most important differential diagnosis is medulloblastoma with lipidized cells. The 
distinction between these 2 lesions is crucial, since medulloblastomas with lipidized cells  
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Figure 12.  
require adjuvant radio/chemotherapy. Most importantly, the growth fraction is in the range 
of 15–40%, which is incompatible with a diagnosis of liponeurocytoma. Cerebellar 
liponeurocytoma is a neoplasm of adults, while lipidized medulloblastomas also occur in 
children (186, 188, 197, 198, 199). The liponeurocytomas may also mimic neoplastic 
oligodendrocytes and clear cell ependymoma (199). 
9.11. Proliferation index 
The Ki-67/ MIB-1 labeling index, is usually in the range of 1–3%, but may be as high as 6%, 
with a mean value of 2.5% . In the adipose component, the MIB-1 labeling index is even 
lower (184, 200). 
9.12. Histogenesis 
An origin from the external granular layer of the cerebellum cannot be ruled out, 
Immunoreactivity to neuronal antigens and GFAP includes cell bodies embracing fat 
globules. This suggests that the fat-containing cells result from lipomatous differentiation of 
tumor cells. The cell of origin is most likely a precursor cell with a preferential commitment 
to neuronal differentiation. (184,185,200). 
9.13. Genetics susceptibility 
Genetic analysis of 20 cerebellar liponeurocytomas revealed TP53 missense mutations in 4 
cases (20%), a frequency significantly higher than that in medulloblastomas (6%). There was 
no case with a PTCH, APC, or ß-catenin mutation, each of which can be present in subsets of 
medulloblastomas. FISH analysis showed that isochromosome 17q, a genetic hallmark 
present in 40% of cerebellar medulloblastomas, was not enountered in any of the cases 
investigated. This finding supports the view that the cerebellar liponeurocytoma is a distinct 
entity and not a variant of medulloblastoma. cDNA expression profiles showed a 
relationship to central neurocytoma, but the presence of TP53 mutations, which are absent 
in central neurocytomas, suggests that they develop through different genetic pathways 
(182). 
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9.14. Prognostis 
A review of published cases indicates that this lesion generally carries a favorable prognosis. 
Because of the rarity of this tumor and the lack of systematic follow-up data, survival and 
recurrence rates must be interpreted with some caution (182, 185).  
Of 21 patients with follow-up data, 6 (29%) died within 6 months to 2 years, 5 (24%) died 
after 2–4 years and 10 (48%) survived 5–16 years after surgical intervention. The 5-year 
survival rate was 48% and the mean overall survival was 5.8 years. However, 62% of 
patients developed a recurrence from 1 to 12 years, and in 3 patients there was a second 
relapse 1 to 5 years later. Despite its aggressive course there is no malignant transformation 
observed. (176). 
10. Filum terminale and spinal paraganglioma 
10.1. Definition 
A distinctive neuroendocrine neoplasm, usually encapsulated, slowgrowing, and benign, 
arising from specialized neural crest cells associated with segmental autonomic ganglia 
(paraganglia); it is composed of uniform chief cells displaying neuronal differentiation and 
forming compact nests (Zellballen), surrounded by sustentacular cells and a delicate 
capillary network. This type of neoplasm is mostly affecting the cauda equine and filum 
terminale 
10.2. Grading 
Paragangliomas of the cauda equine/filum terminale correspond histologically to WHO 
grade I (1). 
10.3. Synonyms and historical annotation 
The early terminology of paragangliomas is not well known. Early authors divided them 
into chromaffin and nonchromaffin on the basis of their reaction with chromic acid. 
However, since this reaction does not reliably reflect their functional activity, current 
terminology is based upon anatomical location as seen in carotid body paraganglioma 
(chemodectoma), jugulotympanic paraganglioma (glomus jugulare tumor).  
10.4. Incidence and location 
Paragangliomas of the CNS are infrequent, the vast majority present as lumber spinal 
intradural tumors in the cauda equina region. Since the first description of cauda equina 
region paraganglioma in 1970 (201), more than 210 cases have been reported. And 174 cases 
reported prior to 2003 (202). Paragangliomas of the cauda equine region comprise 3.4% to 
3.8% of all tumors affecting this region (203, 204). Other spinal levels are involved far less 
often; 14 paragangliomas were reported in the thoracic region, most being extradural with 
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an intravertebral and paraspinal component (205, 206), and 2 tumors involved the cervical 
region (207, 208).  
Intracranial paragangliomas are usually located in the posterior fossa; jugulotympanic 
paragangliomas (209). However, intracranial tumors have also been described. These 
locations include sellar region, the cerebellopontine angle, cerebellar parenchyma, and the 
fronto-temporal lobes ( 210, 211, 212, 213). 
10.5. Age and sex distribution 
Cauda equina paragangliomas generally affect adults. Patient age ranges from 9 to 74 years 
(mean, 46 years), with a slight predominance in males with Male:Female ratio at 1.4:1. 
Jugulotympanic paragangliomas are more common in Caucasians, with a strong female 
preference, and occur mainly in the fifth and sixth decades (209). 
10.6. Clinical features 
The most common presenting symptoms include a long standing history of low-back pain and 
sciatica. Sensory deficit, paraparesis, and sphincter disturbances are common in the later stage, 
while complete cauda equina syndrome is rare. An intracranial hypertension symptoms and 
signs was reported in 8 cases. Only 3 endocrinologically functional paragangliomas of the 
cauda equine region have been reported (214, 215, 216). The few reported paragangliomas of 
the thoracic spine presented with short term of signs of spinal cord compression (217). About 
36% of glomus jugulare paragangliomas extend into the cranial cavity and produce headache, 
pulsatile tinnitus and lower cranial nerve involvement; rarely, signs of catecholamine secretion 
may be seen (209). 
10.7. Neuroimaging 
Cauda equina paragangliomas has no specific features. Most appear as isodense, 
homogeneously enhancing masses on CT. However, since CT without contrast may miss the 
lesion, MRI is the investigation of choice. MRI images typically show a well marked, may be 
with cystic component mass that is hypo- or isointense to spinal cord on T1-weighted 
images, with a vivd contrast enhancemnet. It appears as hyperintense on T2-weighted 
images. The presence of ecstatic and dilated vessels and a low signal intensity rim (“cap 
sign”) on T2-weighted images are considered diagnostically important feature. Plain 
radiographs are usually helpful, and show some scalloping of the vertebral bod y due to 
chronic bone compression (204, 218). Figure 13 
10.8. Histopathology 
Tumors are well differentiated, mimicking normal paraganglia, nearly half of cauda equina 
paragangliomas contain mature ganglion cells, as well as cells transitional between chief and 
ganglion cells. These lesions are composed of chief (type I) cells disposed in nests or lobules 
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(Zellballen pattern), and surrounded by a single layer of sustentacular (type II) cells. The 
Zellballen are surrounded by a delicate capillary network that may undergo sclerosis. The 
uniform round or polygonal chief cells possess central, round-to-oval nuclei, with finely 
stippled chromatin and inconspicuous nucleoli. Cytoplasm varies somewhat in quantity and 
is usually eosinophilic and finely granular. In some conditions, it is amphophilic or clear. 
Sustentacular cells are spindle-shaped. Encompassing the lobules, their long processes are 
often so attenuated that they are undetectable by routine light microscopy, and visible only 
on immunostains for S-100 protein. (219). Such “gangliocytic paragangliomas” are also 
found in other sites such as the duodenum and are analogous to phaeochromocytoma with 
neuronal differentiation. Some paragangliomas of the cauda equina region show 
architectural features similar to carcinoid tumors, including angiomatous, adenomatous, 
and pseudorosette patterns. Tumors composed predominantly of spindle and melanin-
containing cells (melanotic paragangliomas) have also been described at this site, as has 
oncocytic paraganglioma (220, 221, 222). hemorrhagic necrosis may also occur, and scattered 
mitotic figures can be seen. these features are not of prognostic implication (223). Figure 14A 
10.9. Immunohistochemistry 
Chief and sustentacular cells can be identified by biomarkers. Chief cells are marked with 
Neuron-specific enolase (NSE), synaptophysin and chromogranin (228, 229). Chromogranin 
A reactivity parallels the Grimelius (argyrophil) reaction (219, 223,224). Neurofilament 
proteins are also useful markers of chief cells. Expression of serotonin (5H-T) and of various 
neuropeptides (somatostatin, leu, and metenkephalin) has been demonstrated in 
paraganglioma of the cauda equina region. Paranuclear cytkeokeratin immunoreactivity is 
particularly prominent in cauda equina examples. Sustentacular cells are uniformly reactive 
for S-100 protein, and usually show staining for glial fibrillary acidic protein (GFAP). Chief 
cells may also show variable S-100 immunoreactivity (220, 223, 225). Figure 14B 
10.10. Electron microscopy 
The characteristic ultrastructural features of chief cells is the presence of dense core 
(neurosecretory) granules measuring 100 to 400 nm (mean, 140 nm). Depending on their 
cytoplasmic electron density, “light” and “dark” chief cells are recognized. A layer of basal 
lamina is present at the interface of Zellballen and surrounding stroma. In addition to well-
developed Golgi, extensive smooth endoplasmic reticulum, and lysosomes, chief cells may 
contain numerous atypical mitochondria, as well as paranuclear whorls of intermediate 
filaments (223, 226). Sustentacular cells are characterized by an elongated nucleus with 
marginal chromatin, increased cytoplasmic electron density, relative profusion of 
intermediate filaments, and low core granules ( 225, 226, 227). 
10.11. Genetics susceptibility 
It is not clear, there is no reported association of spinal paragangliomas with genetic 
abnormalit. However, Systemic paragangliomas may be multifocal, The association of spinal 
 
Neuronal and Mixed Neuronal-Glial Tumors of the Central Nervous System 229 
paraganglioma with brain tumors, spinal epidural haemangioma, syringomyelia, and 
intramedullary cysts are encountered ( 228, 229, 230, 231), but these associations may be 
coincidental. Several autosomal dominant inherited syndromes predispose to 
paraganglioma or phaeochromocytomaas noted in von Hippel- Lindau disease (VHL); 
multiple endocrine neoplasia type 2 (RET mutations); neurofibromatosis type 1 (NF1). 
Multiple, benign, head and neck paragangliomas are often caused by SDHD mutations, 
while SDHB mutations are associated with phaeochromocytoma. There are only 4 families 
with the SDHC mutation have been identified. Spinal paragangliomas are considered non-
familial, but a study of 22 spinal paragangliomas showed an SDHD germline mutation in 1 
patient with recurrent spinal paraganglioma and a cerebellar metastasis (232). 
10.12. Histogenesis 
The histogenesis is unknow. Some authors favor an origin from paraganglion cells 
associated with regional autonomic nerves and blood vessels (233). Others have suggested 
that peripheral neuroblasts usually present in the adult filum terminale may undergo 
paraganglionic differentiation (229). Jugulotympanic paragangliomas presumably arise from 
microscopic paraganglia within the temporal bone. Some interesting cases have reported the 
coexistence of a paraganglioma and myxopapillary ependymoma in the cauda equina 
region (234, 235). 
10.13. Prognostic factors 
Tumor location is the most important predictive prognostic factor rather than histology of 
paragangliomas. For instance, the metastasis rate of para-aortic paraganglioma is high (28 
to 42%), whereas that of carotid body tumors is only 2 to 9% (236). About 50% of the 
glomus jugulare tumors recur locally, but only 5% with distant metastastases (234, 237). 
The tumor vascularity has no significant value. The vast majority of cauda equina 
paragangliomas are slowly growing and curable by total excision. Based on long-term 
follow-up, it is estimated that 4% will recur following gross total removal (238, 239). 
Metastasis outside the CNS is rare (220). CSF seeding of spinal paragangliomas has been 
reported (240).  
11. Conclusion 
CNS neuroepithelial and neuronal tumours are usually benign and slow growing 
neoplasms with WHO grade I-II. They comprise a low percentage of the whole CNS 
neoplasms and may affect any part of the CNS. These lesions present with non specific 
symptoms and signs; but tend to cause intractable epilepsy when affecting the cerebral 
cortex. Along with clinical presentation and neuroimaging; the histopathology and 
immunochemistry confirm the diagnosis. Surgical resctioning is the treatment of choice with 
favorable prognosis and long term cure; adjuvant treatment is preserved to recurrent 
tumours or to high grade lesions 
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12. Table of summary 
 Location  WHO  Type of cells Specific features  prognosis 
Ganglioglioma 
and 
Gangliocytoma 
Throughout the CNS 
more common in 
Supratentorial. 
Temporal lobe 
predilection  
Grade I 
Garde 
III 
Immature ganglion 
cells and/ or astrocyte 
Large neoplastic ganglion 
cells with/without glial 
components 
Low grade 
favorable 
Higher 
grade : 
variable 
Central 
Neurocytoma 
and 
extraventricular 
Neurocytoma 
Supratentorial. 
Paraventricular 
Grade 
I-II 
Uniform ferentiated 
neurocyte 
Oligodendroglioma-like 
honeycomb appearance, 
irregular “rosettes” 
perivascular pseudorosettes 
Favorable  
Dysembryoplasti
c Neuroepithelial 
tumour 
Temporal lobe and 
mesial region  
Grade I glio-neuronal 
constituent 
columns formed by bundles 
of axons lined by small 
oligodendroglia-like cells 
Favorable 
 DIA , DIG Supratentorial with 
frontal and parietal 
lobes predilection 
Grade I desmoplastic 
leptomeningeal, poorly 
differentiated 
neuroepithelial cells 
Astrocytes are the main 
tumor-cell in DIAs. 
immature neurons in DIGs 
Favorable 
 RGNT 4th ventricle and 
aqueduct cerebellar 
and brain stem 
Grade I a biphasic neurocytic 
and glial architecture.  
The neurocytic rosettes 
,perivascular 
pseudorosettes. 
Favorable 
Papillary  
Glio-neuronal 
tumour 
Temporal lobe  Grade I  small, cuboidal glial 
cells,collections of 
neurocytes,and 
occasionally ganglion 
cells 
pseudopapillary manner 
and  
pseudostratified layer of 
small, cuboidal glial cells,   
interpapillary sheets 
collections of neurocytes, 
ganglion cells.  
Favorable 
Cerebellar 
Liponeurocytoma 
Cerebellar 
hemisphere , vermis 
CP angle, rarely 
supratentorial  
Grade I small neuronal cells 
with focal lipomatous 
differentiation,  
 small neuronal cells with 
the cytology of neurocytes 
and focal lipomatous cella, 
resembling mature adipose 
tissue 
Favorable 
Filum terminale 
and spinal 
paraganglioma 
Cauda equine region. 
Jugulotympaniirial 
arely supratento 
Grade I mature ganglion cells, 
transitional  
cells between chief and 
ganglion cells  
mature ganglion cells, cells 
transitional cells. Chief (type 
I) cells disposed in nests or 
lobules (Zellballen pattern) 
surrounded a delicate 
capillary network, and 
sustentacular (type II) cells. 
Favorable 
Table 1. Summary 
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